Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma Presented ByProf. Thomas Powles, Barts Cancer Centre, London, UK TrialPhase 3, DANUBE ConferenceEAU 2021 31 August, 2021 12:26
First-line immune-combination therapies in mUC TrialPhase 3, KEYNOTE-361 ConferenceESMO 2020 25 November, 2020 14:43